Eyenovia specializes in the commercialization and development of Optejet, a device used for presbyopia and pediatric progressive myopia.
The Redwood facility, which was announced operational in 2022, focuses on Optejet pharmaceutical manufacturing finishing operations, including drug loading, labeling and packaging prior to distribution, according to a June 6 press release.
The new 10,000-square-foot Reno facility will focus on device manufacturing.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
